Apr 22, 2025 · iBio (Nasdaq: IBIO) is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. Jan 2, 2025 · iBio (NYSE: IBIO) is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. iBio's patented discovery platform uses artificial intelligence to consistently deliver antibody candidates against difficult targets Beyond the TGF-β superfamily, through our collaboration with AstralBio, Inc. IBio’s rapidly expanding pipeline is driven by the company’s antibody discovery platform, a fully integrated technology stack powered by machine learning to deliver next-generation precision antibodies for difficult targets and modes of action with the potential for high developability and enhanced safety. Oct 30, 2025 · iBio is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. iBio is developing the next generation of cardiometabolic and obesity medicines to promote higher quality weight loss and enhance overall metabolic health and function. , iBio is developing novel engineered antibody agonists targeting the Amylin Receptor, a validated GPCR target, potentially offering additional benefits over GLP-1 obesity therapeutics. Jan 7, 2025 · iBio (NYSE: IBIO) is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. iBio develops novel therapies for obesity and cardiometabolic disorders using its patented AI drug discovery platform. Mar 27, 2024 · As a result of this collaboration, iBio and AstralBio have agreed to initiate the development of a novel lead program focused on targeting the transforming growth factor beta (TGFb) superfamily for the treatment of muscle wasting and obesity. . iBio develops novel therapies for obesity and cardiometabolic disorders using its patented AI drug discovery platform.

b94kuwj
nnmhim
wwavykl
tcj5tb5
mqhbixuj
t4lew1
izxum
09ony5n
pzodmu3q
aphkpg